Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

574.80INR
20 Feb 2018
Change (% chg)

Rs-8.15 (-1.40%)
Prev Close
Rs582.95
Open
Rs584.00
Day's High
Rs584.45
Day's Low
Rs571.50
Volume
2,126,266
Avg. Vol
2,234,229
52-wk High
Rs809.45
52-wk Low
Rs503.05

Select another date:

Wed, Feb 7 2018

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage:

Aurobindo Pharma Q3 profit up about 3 pct, misses estimates

Feb 7 Aurobindo Pharma Ltd, India's third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts' estimates.

BRIEF-India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct

* DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

BUZZ-India's Aurobindo Pharma down after Q2 results

** Aurobindo Pharma Ltd falls as much as 3.5 pct to 762.20 rupees

Aurobindo Pharma second-quarter profit rises 29 percent, beats estimates

India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

Nov 9 India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says ‍received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg​

MEDIA-India's Aurobindo Pharma in talks to buy Shreya Life Sciences’ Russia business - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

Select another date: